Ground-breaking advancements in immunotherapy are poised to transform cancer care. New data reveal the effectiveness of these immune-boosting drugs in treating a wider range of cancers at their earlier stages. Previously established as life-extending treatments for advanced diseases, drugs such as Bristol Myers Squibb’s Opdivo, AstraZeneca’s Imfinzi, and Roche’s Tecentriq are now demonstrating significant promise. They are preventing recurrence and…